|
covid-19 |
25 |
|
sars-cov-2 |
23 |
|
influenza |
21 |
|
transmission |
16 |
|
disease burden |
15 |
|
surveillance |
14 |
|
public health |
12 |
|
reproduction number |
12 |
|
acute respiratory illness |
11 |
|
coronavirus disease |
11 |
|
infectiousness |
11 |
|
influenza a(h7n9) |
11 |
|
disparities |
10 |
|
epidemiology |
10 |
|
intervention |
10 |
|
socioeconomic |
10 |
|
vaccine effectiveness |
10 |
|
work from home |
10 |
|
coronavirus disease 2019 |
9 |
|
mass testing |
9 |
|
transmission dynamics |
9 |
|
2019 novel coronavirus disease |
8 |
|
behavior change |
8 |
|
control |
8 |
|
coughing |
8 |
|
disease predisposition |
8 |
|
disease surveillance |
8 |
|
disease transmission |
8 |
|
transmissibility |
8 |
|
antibody |
7 |
|
asymptomatic |
7 |
|
clinical epidemiology |
7 |
|
cluster |
7 |
|
family health |
7 |
|
immunity |
7 |
|
importation |
7 |
|
influenza a virus |
7 |
|
influenza a(h5n1) |
7 |
|
reproductive number |
7 |
|
united kingdom |
7 |
|
variant |
7 |
|
avian influenza a (h7n9) |
6 |
|
clinical diagnosis |
6 |
|
clinical prediction rule |
6 |
|
disease outbreaks |
6 |
|
epidemiological monitoring |
6 |
|
generation time |
6 |
|
h7n9 subtype |
6 |
|
hospital emergency setting |
6 |
|
impact |
6 |
|
incubation period |
6 |
|
infectious disease outbreak |
6 |
|
influenza a |
6 |
|
influenza b virus |
6 |
|
influenza in birds - mortality - transmission |
6 |
|
influenza, human - mortality |
6 |
|
interventions |
6 |
|
isolation |
6 |
|
line list |
6 |
|
omicron variants |
6 |
|
oseltamivir |
6 |
|
pandemic preparedness |
6 |
|
pandemic responses |
6 |
|
respiration, artificial - statistics and numerical data |
6 |
|
victoria lineage |
6 |
|
viral loads |
6 |
|
yamagata lineage |
6 |
|
basic reproduction number |
5 |
|
booster dose |
5 |
|
children |
5 |
|
china |
5 |
|
credible interval |
5 |
|
h5n1 |
5 |
|
h5n6 |
5 |
|
h7n9 |
5 |
|
non-influenza respiratory virus |
5 |
|
non-influenza respiratory virus infection |
5 |
|
symptoms |
5 |
|
temporary protection |
5 |
|
vaccination |
5 |
|
viral shedding |
5 |
|
virus interference |
5 |
|
asymptomatic cases |
4 |
|
border control |
4 |
|
correlation |
4 |
|
extended dosing interval |
4 |
|
imported cases |
4 |
|
infection |
4 |
|
influenza activity |
4 |
|
influenza-like illness |
4 |
|
monitoring |
4 |
|
mrna vaccine |
4 |
|
pattern |
4 |
|
predict |
4 |
|
prediction |
4 |
|
preexisting immunity |
4 |
|
school absenteeism |
4 |
|
school attendance |
4 |
|
surveillance tolls |
4 |
|
test-negative design |
4 |
|
trend |
4 |
|
delta |
3 |
|
genetic susceptibility |
3 |
|
hong kong |
3 |
|
human-to-human transmissibility |
3 |
|
omicron |
3 |
|
pre-symptomatic |
3 |
|
secondary attack rate |
3 |
|
severe acute respiratory syndrome coronavirus 2 |
3 |
|
symptomatic |
3 |
|
heterogeneity |
2 |
|
households |
2 |
|
hypertension |
2 |
|
imprinting protection |
2 |
|
population incidence |
2 |
|
sfa |
2 |
|
stroke |
2 |
|
transmission - influenza |
2 |
|
usfa |
2 |
|
acute ischemic stroke |
1 |
|
breakthrough infections |
1 |
|
circulating fatty acids |
1 |
|
community outbreak |
1 |
|
household transmission |
1 |
|
hypertensive |
1 |
|
intervention efficacy |
1 |
|
linoleic acid |
1 |
|
microbiome |
1 |
|
norovirus |
1 |
|
saturated fatty acids |
1 |
|
serial interval |
1 |
|
susceptibility |
1 |
|
unsaturated fatty acids |
1 |
|
viral load |
1 |
